Todd Thomson Sells 280,000 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock

Actuate Therapeutics, Inc. (NASDAQ:ACTU) Director Todd Thomson sold 280,000 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $5.80, for a total transaction of $1,624,000.00. Following the completion of the transaction, the director directly owned 904,795 shares of the company’s stock, valued at $5,247,811. The trade was a 23.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Actuate Therapeutics Trading Down 0.5%

Shares of NASDAQ ACTU traded down $0.03 during midday trading on Wednesday, reaching $6.63. The company had a trading volume of 36,442 shares, compared to its average volume of 129,207. Actuate Therapeutics, Inc. has a 1 year low of $5.47 and a 1 year high of $11.99. The business’s 50-day simple moving average is $6.61 and its 200 day simple moving average is $7.01. The stock has a market cap of $154.08 million, a P/E ratio of -7.62 and a beta of -0.15.

Actuate Therapeutics (NASDAQ:ACTU) last issued its earnings results on Thursday, November 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ACTU shares. Wall Street Zen raised shares of Actuate Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Actuate Therapeutics in a report on Wednesday, November 19th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.33.

Institutional Trading of Actuate Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Voss Capital LP lifted its position in shares of Actuate Therapeutics by 101.0% in the second quarter. Voss Capital LP now owns 286,140 shares of the company’s stock valued at $1,748,000 after acquiring an additional 143,759 shares in the last quarter. BIOS Capital Management LP boosted its stake in Actuate Therapeutics by 0.7% during the 2nd quarter. BIOS Capital Management LP now owns 9,965,079 shares of the company’s stock worth $60,887,000 after purchasing an additional 71,428 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Actuate Therapeutics by 98.7% during the first quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company’s stock worth $151,000 after buying an additional 11,105 shares in the last quarter. Gleason Group Inc. acquired a new stake in shares of Actuate Therapeutics in the second quarter valued at about $116,000. Finally, Sfmg LLC raised its position in shares of Actuate Therapeutics by 32.3% in the second quarter. Sfmg LLC now owns 14,550 shares of the company’s stock valued at $89,000 after buying an additional 3,550 shares during the last quarter.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.